Condition: Unresectable Melanoma · Metastatic Melanoma · Ocular Melanoma · Sponsor: Iovance Biotherapeutics, Inc.
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
This description comes directly from the study's public registry record.
Iovance Biotherapeutics · 1-844-845-4682 · Clinical.Inquiries@iovance.com
Always discuss trial participation with your own doctor first.
| SCRI Oncology Partners- Denver | Denver, Colorado, United States | Recruiting |
| UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| Greenslopes Private Hospital | Greenslopes, Queensland, Australia | Recruiting |
| Hollywood Private Hospital Ramsay | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06940739